Literature DB >> 17325225

Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.

Jennifer Nielsen Kahn1, Guillermo Garcia-Effron, Ming-Jo Hsu, Steven Park, Kieren A Marr, David S Perlin.   

Abstract

A Candida krusei strain from a patient with acute myelogenous leukemia that displayed reduced susceptibility to echinocandin drugs contained a heterozygous mutation, T2080K, in FKS1. The resulting Phe655-->Cys substitution altered the sensitivity of glucan synthase to echinocandin drugs, consistent with a common mechanism for echinocandin resistance in Candida spp.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17325225      PMCID： PMC1855530          DOI： 10.1128/AAC.00067-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences.

Authors:  Dominique Sanglard; Frank C Odds
Journal:  Lancet Infect Dis       Date:  2002-02       Impact factor: 25.071

2.  Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Authors:  S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Characteristics of candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality.

Authors:  M Weinberger; L Leibovici; S Perez; Z Samra; I Ostfeld; I Levi; E Bash; D Turner; A Goldschmied-Reouven; G Regev-Yochay; S D Pitlik; N Keller
Journal:  J Hosp Infect       Date:  2005-10       Impact factor: 3.926

4.  In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.

Authors:  M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

5.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Strain typing and determination of population structure of Candida krusei by multilocus sequence typing.

Authors:  Mette D Jacobsen; Neil A R Gow; Martin C J Maiden; Duncan J Shaw; Frank C Odds
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

7.  In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

Authors:  M A Pfaller; D J Diekema; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

8.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Auxotrophic heterozygosities and the ploidy of Candida parapsilosis and Candida krusei.

Authors:  W L Whelan; K J Kwon-Chung
Journal:  J Med Vet Mycol       Date:  1988-06

10.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079
View more
  51 in total

1.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

2.  Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.

Authors:  Rasmus Hare Jensen; Ulrik Stenz Justesen; Annika Rewes; David S Perlin; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.

Authors:  Marie Desnos-Ollivier; Olivier Moquet; Taieb Chouaki; Anne-Marie Guérin; Françoise Dromer
Journal:  J Clin Microbiol       Date:  2011-04-13       Impact factor: 5.948

4.  Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans.

Authors:  Nathan P Wiederhold; Jodi L Grabinski; Guillermo Garcia-Effron; David S Perlin; Samuel A Lee
Journal:  Antimicrob Agents Chemother       Date:  2008-09-15       Impact factor: 5.191

5.  Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.

Authors:  M A Pfaller; V Chaturvedi; D J Diekema; M A Ghannoum; N M Holliday; S B Killian; C C Knapp; S A Messer; A Miskov; R Ramani
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

6.  Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

Authors:  M A Pfaller; D J Diekema; L Ostrosky-Zeichner; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; M A Ghannoum; C C Knapp; D J Sheehan; T J Walsh
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

7.  Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.

Authors:  John D Cleary; Guillermo Garcia-Effron; Stanley W Chapman; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

Review 8.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

9.  Novel FKS mutations associated with echinocandin resistance in Candida species.

Authors:  Guillermo Garcia-Effron; Daniel Joseph Chua; Jon Rupert Tomada; Joseph DiPersio; David S Perlin; Mahmoud Ghannoum; Hector Bonilla
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

10.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.